PCM
VRTX icon

Parsons Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Parsons Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.31M Buy
9,641
+150
+2% +$69.9K 0.2% 107
2025
Q4 		$4.3M Sell
9,491
-395
-4% -$170K 0.24% 93
2025
Q3 		$3.87M Sell
9,886
-542
-5% -$227K 0.22% 106
2025
Q2 		$4.64M Buy
10,428
+2,660
+34% +$1.23M 0.29% 79
2025
Q1 		$3.77M Buy
7,768
+735
+10% +$343K 0.21% 100
2024
Q4 		$2.83M Buy
7,033
+1,521
+28% +$705K 0.15% 128
2024
Q3 		$2.56M Buy
5,512
+250
+5% +$120K 0.16% 135
2024
Q2 		$2.47M Buy
5,262
+2,591
+97% +$1.12M 0.17% 130
2024
Q1 		$1.12M Buy
2,671
+1,884
+239% +$796K 0.08% 220
2023
Q4 		$320K Buy
787
+100
+15% +$36.9K 0.02% 365
2023
Q3 		$239K Hold
687
– – 0.02% 383
2023
Q2 		$242K Sell
687
-2
-0.3% -$674 0.02% 387
2023
Q1 		$217K Buy
+689
New +$207K 0.02% 398
2021
Q4 		– Sell
-1,268
Closed -$230K – 442
2021
Q3 		$230K Sell
1,268
-1,420
-53% -$277K 0.02% 401
2021
Q2 		$542K Sell
2,688
-723
-21% -$151K 0.04% 283
2021
Q1 		$733K Sell
3,411
-2,618
-43% -$575K 0.06% 236
2020
Q4 		$1.43M Sell
6,029
-70
-1% -$16.1K 0.12% 159
2020
Q3 		$1.66M Buy
6,099
+412
+7% +$114K 0.16% 129
2020
Q2 		$1.65M Buy
5,687
+345
+6% +$93.5K 0.18% 118
2020
Q1 		$1.27M Buy
+5,342
New +$1.23M 0.16% 132

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Parsons Capital Management's VRTX Position: Q1 2026 in Review

Parsons Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q1 2026, buying an estimated $69.9K and bringing the position to 9,641 shares worth $4.31M. The position accounts for 0.2% of the portfolio, ranked #107.

Parsons Capital Management first reported a position in VRTX in Q1 2020 and has held it in 20 quarters since. The position peaked at $4.64M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Parsons Capital Management held 9,641 shares of Vertex Pharmaceuticals worth $4.31M as of Q1 2026.
  • Parsons Capital Management bought 150 Vertex Pharmaceuticals shares in Q1 2026, an estimated $69.9K.
  • Vertex Pharmaceuticals made up 0.2% of Parsons Capital Management's portfolio in Q1 2026, its #107 holding.
  • Parsons Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 20 quarters since.
  • Parsons Capital Management's Vertex Pharmaceuticals position peaked at $4.64M in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Parsons Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.